Fed. Circ. Lets Sanofi, Regeneron Sell Drug In Patent Appeal
Sanofi SA and partner Regeneron Pharmaceuticals can keep selling their cholesterol-lowering drug Praluent while they appeal a jury verdict that upheld Amgen Inc.'s patents for a competing drug therapy, the Federal...To view the full article, register now.
Already a subscriber? Click here to view full article